Alternative immunomodulators
- 1 March 2003
- journal article
- review article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 15 (3) , 245-248
- https://doi.org/10.1097/00042737-200303000-00006
Abstract
There is now a large number of potential immunomodulatory agents that may be of value in inflammatory bowel disease. The newer immunosuppressants, such as tacrolimus and mycophenolate, probably offer little more than providing comparable alternatives to more established agents, and fish oil and other eicosanoid modulators are probably not especially potent if effective. The biological agents, however, bring a more novel and potentially powerful approach. Natalizumab, and targeted mucosal delivery of interleukin-10 already show considerable promise.Keywords
This publication has 19 references indexed in Scilit:
- Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?American Journal of Gastroenterology, 2001
- Oral tacrolimus treatment of severe colitis in childrenThe Journal of Pediatrics, 2000
- Low efficacy of long-term treatment with mycophenolate mofetil in patients with Crohn's diseaseGastroenterology, 2000
- Toxicity of mycophenolate mofetil (MMF) in patients with inflammatory bowel disease (IBD)Gastroenterology, 2000
- Tacrolimus (FK506): A new immunosuppressant for steroid refractory inflammatory bowel disease (IBD)Gastroenterology, 2000
- Mycophenolate mofetil in patients with Crohn's diseaseAmerican Journal of Gastroenterology, 1998
- Course of Crohn's disease after allogeneic marrow transplantationGastroenterology, 1998
- Short-chain fatty acid enemasDiseases of the Colon & Rectum, 1992
- Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial.Gut, 1992
- Dietary Supplementation with Fish Oil in Ulcerative ColitisAnnals of Internal Medicine, 1992